Resistance to AC220 in FLT3-ITD+ AML is mediated by a secondary FLT3-ITD F691L mutation

被引：0
|
作者：
Albers, C. [1 ]
Leischner, H. [1 ,2 ]
Verbeek, M. [1 ]
Yu, C. [1 ]
von Bubnoff, N. [1 ]
Peschel, C. [1 ]
Duyster, J. [1 ]
机构：
[1] III Med Dept, Munich, Germany
[2] HELIOS Klinikum Berlin Buch, Dept Hematol Oncol & Tumor Immunol, Berlin, Germany
来源：
ONKOLOGIE | 2012年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：117 / 117
页数：1
相关论文
共 50 条
  • [21] Flt3/ITD Confers Resistance to FLT3 Inhibitor AC220 By up-Regulating Runx1
    Hirade, Tomohiro
    Abe, Mariko
    Onishi, Chie
    Yamaguchi, Seiji
    Fukuda, Seiji
    BLOOD, 2014, 124 (21)
  • [22] Role of Autophagy in Resistance of FLT3-ITD AML Stem Cells to FLT3 TKI Treatment
    Qiu, Shaowei
    Yan, Chengcheng
    Paterson, Andrew J.
    Li, Hui
    Anderson, Nick
    Abraham, Ajay
    He, Jianbo
    Shah, Mansi
    Agarwal, Puneet
    Yang, Jing
    Xie, Min
    Lu, Rui
    Welner, Rob S.
    Bhatia, Ravi
    BLOOD, 2019, 134
  • [23] Bone Marrow Stromal Cells Protect Both FLT3-ITD and FLT3-WT Primary AML Cells from the Anti-Leukemic Activity of the FLT3 Inhibitor AC220
    Dos Santos, Cedric
    Ndikuyeze, Georges Habineza
    Nisssan, Michael
    Zhou, Chenghui
    Shan, Xiaochuan
    Perl, Alexander E.
    Carroll, Martin P.
    Danet-Desnoyers, Gwenn
    BLOOD, 2014, 124 (21)
  • [24] Notch blockade overcomes endothelial cell-mediated resistance of FLT3/ITD-positive AML progenitors to AC220 treatment
    Le, Quy
    Hadland, Brandon
    Meshinchi, Soheil
    Bernstein, Irwin
    LEUKEMIA, 2021, 35 (02) : 601 - 605
  • [25] Notch blockade overcomes endothelial cell-mediated resistance of FLT3/ITD-positive AML progenitors to AC220 treatment
    Quy Le
    Brandon Hadland
    Soheil Meshinchi
    Irwin Bernstein
    Leukemia, 2021, 35 : 601 - 605
  • [26] Novel Small Molecule FLT3 Inhibitors for the Treatment of FLT3-ITD AML
    Melgar, Katelyn
    Walker, MacKenzie
    Jiang, Jian-kang
    Wilson, Kelli
    Mulloy, James C.
    Thomas, Craig J.
    Starczynowski, Daniel T.
    BLOOD, 2015, 126 (23)
  • [27] Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML
    H Wu
    C Hu
    A Wang
    E L Weisberg
    W Wang
    C Chen
    Z Zhao
    K Yu
    J Liu
    J Wu
    A Nonami
    L Wang
    B Wang
    R M Stone
    S Liu
    J D Griffin
    J Liu
    Q Liu
    Leukemia, 2016, 30 : 754 - 757
  • [28] Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML
    Wu, H.
    Hu, C.
    Wang, A.
    Weisberg, E. L.
    Wang, W.
    Chen, C.
    Zhao, Z.
    Yu, K.
    Liu, J.
    Wu, J.
    Nonami, A.
    Wang, L.
    Wang, B.
    Stone, R. M.
    Liu, S.
    Griffin, J. D.
    Liu, J.
    Liu, Q.
    LEUKEMIA, 2016, 30 (03) : 754 - 757
  • [29] Physiologic hypoxia of 6% O2 regulates FLT3-ITD expression and function in AML cell-lines harbouring a FLT3-ITD mutation
    Sironi, S.
    Wagner, M.
    Drolle, H.
    Vasold, J.
    Hiddemann, W.
    Fiegl, M.
    ONKOLOGIE, 2012, 35 : 117 - 118
  • [30] FLT3-ITD Mutation in Relation to FLT3 Expression in Pediatric AML: A Prospective Study from India
    Sharawat, Surender Kumar
    Bakhshi, Radhika
    Vishnubhatla, Sreenivas
    Gupta, Ritu
    Bakhshi, Sameer
    PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2014, 31 (02) : 131 - 137
12345